The Expression Levels of Matrix Metalloproteinases Inhibitors TIMP1, TIMP2 and Matrix Metalloproteinases MMP2, MMP9 in Iraqi Patients Diagnosed with Colon Cancer

Abstract

Colon cancer is the third most common cancer worldwide, responsible for more than half a million deaths every year. Metalloproteinases (MMP2 and MMP9) participate in tumor invasion and metastasis because of their ability to degrade the extracellular matrix (ECM).

Materials and Methods:

The expression levels of MMP2 and MMP9 as well as tissue inhibitor metalloproteinases TIMP1 and TIMP2 were determined by immunohistochemistry in 42 Iraqi patients diagnosed with colon cancer as well as in 18 benign tissues.

Results:

Immunohistochemistry revealed that the protein expression levels of MMP2 ,MMP9, TIMP1 and TIMP2 increased by 83%, 72%, 64%, and 57%, respectively, in patients with colon cancer tissues compared with 19%, 28%, 23%, and 16%, respectively, in benign tissues.

Conclusion:

MMP2, MMP9, TIMP1 and TIMP2 expression levels in Iraqi patients with colon cancer could be used as potential markers that can predict tumor behavior, progression, and prognosis.